Lavezzi A M, Santambrogio L, Bellaviti N, Biondo B, Nosotti M, Radice F, Matturri L
Institute of Pathology, University of Milan, Milan, Italy.
Oncol Rep. 1999 Jul-Aug;6(4):819-25. doi: 10.3892/or.6.4.819.
The purpose of our study was to examine the prognostic significance of different biomarkers [DNA content, proliferating cell nuclear antigen labeling index (PCNA-LI), p53 mutation and apoptosis], in 152 surgically resected non-small cell lung cancer (NSCLC). The ploidy was carried out by densitometry; PCNA-LI, p53 and apoptosis were determined with immunohistochemistry. The results were correlated to histology, stage and patient survival. A considerable variability of the PCNA indices, ranging from 0 to 33.5% with a mean value of 7.0%, was found. DNA evaluation showed a prevalence of aneuploid tumors (62%) with a DNA index >1. Overexpression of p53 protein and apoptotic positivity were observed in low percentages of cases (16% and 32% respectively). Only stage and PCNA-LI were found to be significant prognostic factors on multivariate analysis. PCNA was superior to stage in predicting shortened survival of patients with NSCLC. PCNA immunostaining can be applied on a routine basis in formalin-fixed, paraffin-embedded samples of NSCLC to predict patient prognosis and thus to identify patients in need of additional postoperative therapies.
我们研究的目的是检测152例手术切除的非小细胞肺癌（NSCLC）中不同生物标志物[DNA含量、增殖细胞核抗原标记指数（PCNA-LI）、p53突变和凋亡]的预后意义。通过密度测定法进行倍体分析；采用免疫组织化学法测定PCNA-LI、p53和凋亡情况。将结果与组织学、分期和患者生存率进行关联分析。发现PCNA指数存在显著差异，范围为0至33.5%，平均值为7.0%。DNA评估显示非整倍体肿瘤占比62%，DNA指数>1。p53蛋白过表达和凋亡阳性在低比例病例中观察到（分别为16%和32%）。多因素分析显示只有分期和PCNA-LI是显著的预后因素。在预测NSCLC患者生存期缩短方面，PCNA优于分期。PCNA免疫染色可常规应用于NSCLC福尔马林固定、石蜡包埋样本，以预测患者预后，从而识别需要额外术后治疗的患者。
